TY - JOUR
T1 - Comparison of Donor Sources in Hematopoietic Stem Cell Transplantation for Childhood Acute Leukemia
T2 - A Nationwide Retrospective Study
AU - the Donor/Source Working Group of Japan Society of Hematopoietic Cell Transplantation
AU - Sakaguchi, Hirotoshi
AU - Watanabe, Nobuhiro
AU - Matsumoto, Kimikazu
AU - Yabe, Hiromasa
AU - Kato, Shunichi
AU - Ogawa, Atsushi
AU - Inagaki, Jiro
AU - Goto, Hiroaki
AU - Koh, Katsuyoshi
AU - Yoshida, Nao
AU - Kato, Keisuke
AU - Cho, Yuko
AU - Kosaka, Yoshiyuki
AU - Takahashi, Yoshiyuki
AU - Inoue, Masami
AU - Kato, Koji
AU - Atsuta, Yoshiko
AU - Miyamura, Koichi
N1 - Funding Information:
The authors thank all the participating doctors and patients involved in the Transplant Registry Unified Management Program (TRUMP) in collaboration with the Japanese Data Center for Hematopoietic Cell Transplantation, Japan Society for Hematopoietic Cell Transplantation, Japan Society for Pediatric Hematology and Oncology, Japan Marrow Donor Program, Cord Blood Banks, and Japanese Red Cross Society. This work was supported in part by a research grant for Allergic Disease and Immunology from the Ministry of Health, Labour and Welfare, Japan (grant no. 16ek0510004h0003 ).
Funding Information:
The authors thank all the participating doctors and patients involved in the Transplant Registry Unified Management Program (TRUMP) in collaboration with the Japanese Data Center for Hematopoietic Cell Transplantation, Japan Society for Hematopoietic Cell Transplantation, Japan Society for Pediatric Hematology and Oncology, Japan Marrow Donor Program, Cord Blood Banks, and Japanese Red Cross Society. This work was supported in part by a research grant for Allergic Disease and Immunology from the Ministry of Health, Labour and Welfare, Japan (grant no. 16ek0510004h0003).
Publisher Copyright:
© 2016 The American Society for Blood and Marrow Transplantation
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the best therapeutic option for childhood high-risk acute leukemia. However, which donor source is optimal for children lacking an identical sibling remains unclear. To evaluate the clinical impact of donor source on allo-HSCT in childhood acute leukemia, we analyzed data from 577 children who underwent allo-HSCT after a myeloablative regimen during first or second complete remission from 2005 to 2012, using registry data of the Japan Society for Hematopoietic Cell Transplantation, and we compared outcomes of 7/8 to 8/8 HLA allelic–matched unrelated bone marrow transplantation (UR-BMT, n = 218) and 4/6 to 6/6 HLA allelic–matched unrelated cord blood transplantation (UR-CBT, n = 200) to those of HLA-identical related bone marrow transplantation (ID-BMT, n = 159). The median follow-up of survivors was 40.0 months. Three-year overall survival (OS) and leukemia-free survival (LFS) rates for ID-BMT, UR-BMT, and UR-CBT were 74.8% and 69.0%, 75.0% and 69.6%, and 71.8% and 63.8%, respectively. The multivariate analysis demonstrated that OS and LFS for the 3 groups are comparable, although UR-CBT carries a greater risk of nonrelapse mortality (hazard ratio, 2.20; P = .03, compared to ID-BMT) in the myeloablative setting for childhood high-risk acute leukemia.
AB - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the best therapeutic option for childhood high-risk acute leukemia. However, which donor source is optimal for children lacking an identical sibling remains unclear. To evaluate the clinical impact of donor source on allo-HSCT in childhood acute leukemia, we analyzed data from 577 children who underwent allo-HSCT after a myeloablative regimen during first or second complete remission from 2005 to 2012, using registry data of the Japan Society for Hematopoietic Cell Transplantation, and we compared outcomes of 7/8 to 8/8 HLA allelic–matched unrelated bone marrow transplantation (UR-BMT, n = 218) and 4/6 to 6/6 HLA allelic–matched unrelated cord blood transplantation (UR-CBT, n = 200) to those of HLA-identical related bone marrow transplantation (ID-BMT, n = 159). The median follow-up of survivors was 40.0 months. Three-year overall survival (OS) and leukemia-free survival (LFS) rates for ID-BMT, UR-BMT, and UR-CBT were 74.8% and 69.0%, 75.0% and 69.6%, and 71.8% and 63.8%, respectively. The multivariate analysis demonstrated that OS and LFS for the 3 groups are comparable, although UR-CBT carries a greater risk of nonrelapse mortality (hazard ratio, 2.20; P = .03, compared to ID-BMT) in the myeloablative setting for childhood high-risk acute leukemia.
UR - http://www.scopus.com/inward/record.url?scp=84994056122&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994056122&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2016.09.020
DO - 10.1016/j.bbmt.2016.09.020
M3 - Article
C2 - 27667011
AN - SCOPUS:84994056122
SN - 1083-8791
VL - 22
SP - 2226
EP - 2234
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 12
ER -